Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

760

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

mOPV2 at 6 and 7 weeks of age

Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age

BIOLOGICAL

mOPV2 at 6 and 8 weeks of age

Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age

BIOLOGICAL

mOPV2 at 6 and 10 weeks of age

Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age

BIOLOGICAL

IPV at 6 weeks of age

Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age

Trial Locations (1)

Unknown

International Center for Diarrhoeal Disease Research, Bangladesh, Dhaka

All Listed Sponsors
collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

lead

Centers for Disease Control and Prevention

FED

NCT02643368 - Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine | Biotech Hunter | Biotech Hunter